Results 21 to 30 of about 38,575 (293)

Furin is the major proprotein convertase required for KISS1-to-Kisspeptin processing. [PDF]

open access: yesPLoS ONE, 2014
KISS1 is a broadly functional secreted proprotein that is then processed into small peptides, termed kisspeptins (KP). Since sequence analysis showed cleavage at KR or RR dibasic sites of the nascent protein, it was hypothesized that enzyme(s) belonging ...
Sitaram Harihar   +4 more
doaj   +1 more source

Furin Regulates the Alveolarization of Neonatal Lungs in a Mouse Model of Hyperoxic Lung Injury

open access: yesBiomolecules, 2023
Despite advances in treatment options, such as corticosteroid administration and less invasive respiratory support, bronchopulmonary dysplasia (BPD) remains an important prognostic factor in preterm infants.
Shin Kato   +5 more
doaj   +1 more source

Cationic Cell-Penetrating Peptides Are Potent Furin Inhibitors. [PDF]

open access: yesPLoS ONE, 2015
Cationic cell-penetrating peptides have been widely used to enhance the intracellular delivery of various types of cargoes, such as drugs and proteins.
Bruno Ramos-Molina   +7 more
doaj   +1 more source

New Insight Into Metformin-Induced Cholesterol-Lowering Effect Crosstalk Between Glucose and Cholesterol Homeostasis via ChREBP (Carbohydrate-Responsive Element-Binding Protein)-Mediated PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Regulation.

open access: yesArteriosclerosis, Thrombosis and Vascular Biology, 2021
OBJECTIVE Metformin, a first-line drug for treating individuals with type 2 diabetes, exerts beneficial effects on cholesterol-lowering, yet its precise mechanism has not been established.
Die Hu   +11 more
semanticscholar   +1 more source

Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways

open access: yesInternational Journal of Molecular Sciences, 2021
Background: Proprotein convertase subtilisin kexin type 9 inhibitors (PCSK9i) lower LDL-cholesterol and slow atherosclerosis preventing cardiovascular events.
V. Cammisotto   +18 more
semanticscholar   +1 more source

Hysteretic behavior of proprotein convertase 1/3 (PC1/3). [PDF]

open access: yesPLoS ONE, 2011
The proprotein convertases (PCs) are calcium-dependent proteases responsible for processing precursor proteins into their active forms in eukariotes.
Marcelo Y Icimoto   +9 more
doaj   +1 more source

Sex difference in circulating PCSK9 and its clinical implications

open access: yesFrontiers in Pharmacology, 2022
Proprotein convertase subtilisin kexin type 9 (PCSK9) is a proprotein convertase that increases plasma low-density lipoprotein cholesterol (LDL-C) levels by triggering the degradation of LDL receptors (LDLRs).
Fang Jia   +4 more
doaj   +1 more source

Proprotein Convertase Is the Highest-Level Activator of the Alternative Complement Pathway in the Blood

open access: yesJournal of Immunology, 2021
Key Points MASP-3 circulates mainly as an active enzyme and activates pro–factor D. MASP-3 is activated by the proprotein convertase, PCSK6, in the blood. Our discovery links the complement and the proprotein convertase systems. Visual Abstract Factor D (
G. Oroszlán   +9 more
semanticscholar   +1 more source

OFF-State-Specific Inhibition of the Proprotein Convertase Furin

open access: yesACS Chemical Biology, 2021
The pro-protein convertase furin is a highly specific serine protease involved in the proteolytic maturation of many proteins in the secretory pathway.
S. O. Dahms   +4 more
semanticscholar   +1 more source

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

open access: yesStroke, 2020
Supplemental Digital Content is available in the text. Background and Purpose— The PCSK9 (proprotein convertase subtilisin-kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5–1.2) mmol/L and ...
R. Giugliano   +11 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy